Showing posts with label patent market approval linkage. Show all posts
Showing posts with label patent market approval linkage. Show all posts

IPT Decided One of 2 Patents on Herceptin (trastuzumab) Listed in Green List of KFDA as being Invalid

›
Roche launched Herceptin for the treatment of HER2-positive metastatic breast cancer in Korea. And Celltrion, a Korean Pharmaceutical compa...

Reverse Payment Agreement violates Antitrust Law in Korea: the First case decision by the Korean Supreme Court for GSK v. KFTC case on Feb. 27, 2014

›
1. Background GSK owned a Korean patent for ondansetron, antiemetic drug and sold with a tradename as Zofran. Dong-A Pharmaceutical ...

Patent Marketing Approval Linkage

›
The FTA between Korea and USA includes provisions regarding the patent drug market approval (MA) linkage. Pursuant to the KORUS FTA, Korea h...

Denied Patent Term Extension for Novartis' Exelon® Patch in Korea

›
Novartis' Exelon® Patch has been used to treat mild to moderate dementia of the Alzheimer's type and mild to moderate dementia assoc...

Patent Term Extension (PTE) Based on MA for Drug Inventions in Korea

›
1. History of Changes The patent term extension system was first introduced in Korea on July 1, 1987. Under the 1987 Act, a petiti...

Patent and Drug Market Approval Linkage in Korea

›
The FTA between Korea and USA includes provisions regarding the patent drug market approval (MA) linkage. Pursuant to the KORUS FTA, Korea ...